237 related articles for article (PubMed ID: 27865177)
1. Association of plasma xanthine oxidoreductase activity with severity and clinical outcome in patients with chronic heart failure.
Otaki Y; Watanabe T; Kinoshita D; Yokoyama M; Takahashi T; Toshima T; Sugai T; Murase T; Nakamura T; Nishiyama S; Takahashi H; Arimoto T; Shishido T; Miyamoto T; Kubota I
Int J Cardiol; 2017 Feb; 228():151-157. PubMed ID: 27865177
[TBL] [Abstract][Full Text] [Related]
2. Characteristics of Patients with an Abnormally Decreased Plasma Xanthine Oxidoreductase Activity in Acute Heart Failure Who Visited the Emergency Department.
Shirakabe A; Okazaki H; Matsushita M; Shibata Y; Goda H; Shigihara S; Asano K; Tani K; Kiuchi K; Murase T; Nakamura T; Kobayashi N; Hata N; Asai K; Shimizu W
Cardiology; 2020; 145(8):473-480. PubMed ID: 32615578
[TBL] [Abstract][Full Text] [Related]
3. Relationship between plasma xanthine oxidoreductase activity and left ventricular ejection fraction and hypertrophy among cardiac patients.
Fujimura Y; Yamauchi Y; Murase T; Nakamura T; Fujita SI; Fujisaka T; Ito T; Sohmiya K; Hoshiga M; Ishizaka N
PLoS One; 2017; 12(8):e0182699. PubMed ID: 28797123
[TBL] [Abstract][Full Text] [Related]
4. Prognostic impact of plasma xanthine oxidoreductase activity in patients with heart failure with atrial fibrillation.
Watanabe K; Arimoto T; Watanabe T; Otaki Y; Murase T; Nakamura T; Kobayashi Y; Aono T; Saito Y; Koyama K; Hashimoto N; Kutsuzawa D; Kato S; Tamura H; Nishiyama S; Takahashi H; Watanabe M
J Cardiol; 2023 May; 81(5):469-475. PubMed ID: 36822544
[TBL] [Abstract][Full Text] [Related]
5. Impact of plasma xanthine oxidoreductase activity in patients with heart failure with preserved ejection fraction.
Watanabe K; Watanabe T; Otaki Y; Shishido T; Murase T; Nakamura T; Kato S; Tamura H; Nishiyama S; Takahashi H; Arimoto T; Watanabe M
ESC Heart Fail; 2020 Aug; 7(4):1735-1743. PubMed ID: 32432414
[TBL] [Abstract][Full Text] [Related]
6. Plasma xanthine oxidoreductase activity in patients with decompensated acute heart failure requiring intensive care.
Okazaki H; Shirakabe A; Matsushita M; Shibata Y; Sawatani T; Uchiyama S; Tani K; Murase T; Nakamura T; Takayasu T; Asano M; Kobayashi N; Hata N; Asai K; Shimizu W
ESC Heart Fail; 2019 Apr; 6(2):336-343. PubMed ID: 30620450
[TBL] [Abstract][Full Text] [Related]
7. Unexpected high plasma xanthine oxidoreductase activity in female subjects with low levels of uric acid.
Furuhashi M; Mori K; Tanaka M; Maeda T; Matsumoto M; Murase T; Nakamura T; Koyama M; Moniwa N; Ohnishi H; Saitoh S; Shimamoto K; Miura T
Endocr J; 2018 Nov; 65(11):1083-1092. PubMed ID: 30068899
[TBL] [Abstract][Full Text] [Related]
8. Independent association of plasma xanthine oxidoreductase activity with serum uric acid level based on stable isotope-labeled xanthine and liquid chromatography/triple quadrupole mass spectrometry: MedCity21 health examination registry.
Kurajoh M; Fukumoto S; Emoto M; Murase T; Nakamura T; Ishihara T; Go H; Yamamoto K; Nakatani S; Tsuda A; Yamada S; Morioka T; Mori K; Imanishi Y; Inaba M
Clin Chem Lab Med; 2020 Apr; 58(5):780-786. PubMed ID: 31085741
[TBL] [Abstract][Full Text] [Related]
9. Xanthine oxidoreductase activity is correlated with insulin resistance and subclinical inflammation in young humans.
Washio KW; Kusunoki Y; Murase T; Nakamura T; Osugi K; Ohigashi M; Sukenaga T; Ochi F; Matsuo T; Katsuno T; Moriwaki Y; Yamamoto T; Namba M; Koyama H
Metabolism; 2017 May; 70():51-56. PubMed ID: 28403945
[TBL] [Abstract][Full Text] [Related]
10. Increased plasma xanthine oxidoreductase activity deteriorates coronary artery spasm.
Watanabe K; Shishido T; Otaki Y; Watanabe T; Sugai T; Toshima T; Takahashi T; Yokoyama M; Kinoshita D; Murase T; Nakamura T; Wanezaki M; Tamura H; Nishiyama S; Takahashi H; Arimoto T; Yamauchi S; Yamanaka T; Miyamoto T; Kubota I; Watanabe M
Heart Vessels; 2019 Jan; 34(1):1-8. PubMed ID: 29936631
[TBL] [Abstract][Full Text] [Related]
11. Xanthine oxidoreductase activity is associated with serum uric acid and glycemic control in hemodialysis patients.
Nakatani A; Nakatani S; Ishimura E; Murase T; Nakamura T; Sakura M; Tateishi Y; Tsuda A; Kurajoh M; Mori K; Emoto M; Inaba M
Sci Rep; 2017 Nov; 7(1):15416. PubMed ID: 29133805
[TBL] [Abstract][Full Text] [Related]
12. Annual change in plasma xanthine oxidoreductase activity is associated with changes in liver enzymes and body weight.
Furuhashi M; Koyama M; Matsumoto M; Murase T; Nakamura T; Higashiura Y; Tanaka M; Moniwa N; Ohnishi H; Saitoh S; Shimamoto K; Miura T
Endocr J; 2019 Sep; 66(9):777-786. PubMed ID: 31130575
[TBL] [Abstract][Full Text] [Related]
13. Association of plasma xanthine oxidoreductase activity with blood pressure affected by oxidative stress level: MedCity21 health examination registry.
Yoshida S; Kurajoh M; Fukumoto S; Murase T; Nakamura T; Yoshida H; Hirata K; Inaba M; Emoto M
Sci Rep; 2020 Mar; 10(1):4437. PubMed ID: 32157204
[TBL] [Abstract][Full Text] [Related]
14. Plasma xanthine oxidoreductase (XOR) activity in patients who require cardiovascular intensive care.
Shibata Y; Shirakabe A; Okazaki H; Matsushita M; Goda H; Shigihara S; Asano K; Kiuchi K; Tani K; Murase T; Nakamura T; Kobayashi N; Hata N; Asai K; Shimizu W
Heart Vessels; 2020 Oct; 35(10):1390-1400. PubMed ID: 32342210
[TBL] [Abstract][Full Text] [Related]
15. Plasma Xanthine Oxidoreductase Activity Associated with Glycemic Control in Patients with Pre-Dialysis Chronic Kidney Disease.
Nakatani S; Ishimura E; Murase T; Nakamura T; Nakatani A; Toi N; Nishide K; Uedono H; Tsuda A; Kurajoh M; Yamada S; Mori K; Inaba M; Emoto M
Kidney Blood Press Res; 2021; 46(4):475-483. PubMed ID: 34082427
[TBL] [Abstract][Full Text] [Related]
16. Independent links between plasma xanthine oxidoreductase activity and levels of adipokines.
Furuhashi M; Matsumoto M; Murase T; Nakamura T; Higashiura Y; Koyama M; Tanaka M; Moniwa N; Ohnishi H; Saitoh S; Shimamoto K; Miura T
J Diabetes Investig; 2019 Jul; 10(4):1059-1067. PubMed ID: 30516339
[TBL] [Abstract][Full Text] [Related]
17. A highly sensitive assay of human plasma xanthine oxidoreductase activity using stable isotope-labeled xanthine and LC/TQMS.
Murase T; Nampei M; Oka M; Miyachi A; Nakamura T
J Chromatogr B Analyt Technol Biomed Life Sci; 2016 Dec; 1039():51-58. PubMed ID: 27816314
[TBL] [Abstract][Full Text] [Related]
18. Greater coronary lipid core plaque assessed by near-infrared spectroscopy intravascular ultrasound in patients with elevated xanthine oxidoreductase: a mechanistic insight.
Saito Y; Mori N; Murase T; Nakamura T; Akari S; Saito K; Matsuoka T; Tateishi K; Kadohira T; Kitahara H; Fujimoto Y; Kobayashi Y
Heart Vessels; 2021 May; 36(5):597-604. PubMed ID: 33219412
[TBL] [Abstract][Full Text] [Related]
19. New insights into purine metabolism in metabolic diseases: role of xanthine oxidoreductase activity.
Furuhashi M
Am J Physiol Endocrinol Metab; 2020 Nov; 319(5):E827-E834. PubMed ID: 32893671
[TBL] [Abstract][Full Text] [Related]
20. The significance of serum xanthine oxidoreductase in patients with nonalcoholic fatty liver disease.
Zhang J; Xu C; Zhao Y; Chen Y
Clin Lab; 2014; 60(8):1301-7. PubMed ID: 25185415
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
